# Antibody cancer drug developer Tarexis, which finds new targets using real patient data, presents its drug pipeline at a Songdo exhibition

- Link: https://wowtale.net/2026/11/18/268288/?utm_source=rss&utm_medium=rss&utm_campaign=%25ec%258b%25a0%25ea%25b7%259c-%25ed%2591%259c%25ec%25a0%2581-%25ea%25b8%25b0%25eb%25b0%2598-%25eb%2582%259c%25ec%25b9%2598%25ec%2595%2594-adc-%25ec%258b%25a0%25ec%2595%25bd-%25ed%2583%2580%25eb%25a0%2589%25ec%258b%259c%25ec%258a%25a4-%25ed%2591%259c%25ec%25a0%2581-%25eb%25b0%259c%25ea%25b5%25b4%25c2%25b7%25ea%25b2%2580
- Discussion: https://startupxo.com/en/1415/
- Posted by startupxo at 2026-11-18T12:28:08.249Z
- 0 points, 0 comments, kind story, origin curated
- Written in ko, machine translated to en

## Summary

- Tarexis develops antibody-based cancer drugs aimed at new drug targets that it finds using real patient data, for patients with rare or hard-to-treat cancers who cannot use existing targeted therapies. It was founded in December 2025.
- The company explains that most patients with major solid cancers have no valid target, and that they depend on immuno-oncology drugs or chemotherapy, which have limited effect.
- The company believes competition is fierce in ADCs, therapies that attach a powerful anticancer drug to an antibody, because development is concentrated on proven targets such as HER2, TROP2 and MET. It says the rate at which new drugs that worked in animal models are reproduced in human clinical trials is below 10%.
- The company's 3R strategy starts from unmet needs in clinical practice, selects targets using real patient data, and validates efficacy with patient-derived samples. In its pipeline, TX-101 to 103 are at the hit and lead antibody stage, and the rest are at the target discovery stage.

## Sources

- 와우테일: https://wowtale.net/2026/11/18/268288/?utm_source=rss&utm_medium=rss&utm_campaign=%25ec%258b%25a0%25ea%25b7%259c-%25ed%2591%259c%25ec%25a0%2581-%25ea%25b8%25b0%25eb%25b0%2598-%25eb%2582%259c%25ec%25b9%2598%25ec%2595%2594-adc-%25ec%258b%25a0%25ec%2595%25bd-%25ed%2583%2580%25eb%25a0%2589%25ec%258b%259c%25ec%258a%25a4-%25ed%2591%259c%25ec%25a0%2581-%25eb%25b0%259c%25ea%25b5%25b4%25c2%25b7%25ea%25b2%2580

## Comments (0)

No comments yet.

JSON: https://startupxo.com/api/v1/item.json?id=1415&lang=en
